Drug intelligence / Profile preview

RST-500

Development stage: Preclinical
Lead developer: ReST Therapeutics
Modality: Small Molecules

Overview

RST-500 is a small molecule NMDA receptor (NMDAR) modulator specifically targeting the GluN2D subunit, currently in preclinical development by ReST Therapeutics. It is being investigated for 'Radiomize,' a radiotherapy-related indication. The drug is part of a molecular platform designed to address NMDAR overactivation in neuropsychiatric and neurodegenerative contexts. By selectively inhibiting or modulating the GluN2D subunit, RST-500 aims to provide neuroprotection and facilitate recovery from stress or injury associated with radiotherapy.

Targets

GRIN2D (Glutamate receptor ionotropic NMDA subunit 2D)

Beyond the preview

Go deeper on RST-500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RST-500.

Explore the full profile